ClinicalTrials.gg
CompletedNCT02403271Updated Jan 3, 2019Results posted

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

A Phase 1/2 interventional study of Ibrutinib and Durvalumab in Non-Small Cell Lung Cancer, Breast Cancer and Pancreatic Cancer, sponsored by Pharmacyclics LLC.. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-03.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
124
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
30th of 94
124 · median 74
Started
2015
with 6 others
Phase 1/2
4 of 94
none open now
Registered
11th of 94
by date

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 30th largest by enrollment, is one of 7 that started in 2015, is one of 4 in phase 1/2, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid tumors.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Breast Cancer
  • Pancreatic Cancer

Keywords

  • Pharmacyclics
  • PCYC
  • Ibrutinib
  • Durvalumab (MEDI4736)
  • Relapsed Refractory Solid Tumor
  • Non-Small Cell Lung Cancer
  • NSCLC
  • Squamous
  • Squamous NSCLC
  • Squamous Non-Small Cell Lung Cancer
  • Immunotherapy
  • IMBRUVICA®
  • Tumor Immunotherapy
  • Anti-PD-L1
  • Lung Cancer
  • Breast Cancer
  • Triple Negative
  • HER2 Positive
  • HER2 + Breast Cancer
  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed: Non-small cell lung cancer (NSCLC, adenocarcinoma or squamous-cell carcinoma), Breast Cancer ( positive or triple negative), Pancreatic Cancer (adenocarcinoma)
  2. disease (Stage III or IV): NSCLC or pancreatic cancer must have failed at least 1 prior treatment. Breast cancer must have failed at least 2 prior treatments.
  3. by 1.1
  4. Adequate hematologic function:

    • >1500 cells/mm3
    • count >100,000 cells/mm3
    • HGB >9.0 g/dL
  5. Adequate hepatic and renal function:

    • and ALT ≤2.5 x for subjects without liver and ≤3.5 x ULN for subjects with liver metastases
    • ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
    • Creatinine ≤2.0 x ULN and ≥40 mL/min (Cockcroft-Gault or 24-hour creatinine clearance collection)
  6. \<1.5 x ULN and PTT/ aPTT \<1.5 x ULN

Exclusion criteria

Exclusion Criteria:

  1. Mixed small cell and NSCLC histology
  2. A history of CNS involvement except as follows: Subjects with previously treated that are adequately treated with whole brain radiotherapy, that are neurologically stable, and do not require for symptomatic management for at least 14 days prior to first dose of study drug. There must be no clear evidence of radiographically active disease for at least 90 days prior to enrollment.
  3. Anti-tumor therapy within 21 days of study Day 1
  4. Prior treatment with ibrutinib or other BTK inhibitor anti-CD137 or antibody. The following are exceptions to this criterion: Subjects previously treated with an anti-PD1, anti-PD-L1, or anti-PD-L2 antibody.
  5. History of allogeneic organ transplant
  6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Phase 1b

    In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6+3 dose de-escalation design and will include a sentinel participant which will have a 3-day observation period prior to dosing of subsequent participants. Participants with one of the following three tumor types will be eligible for enrollment: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma).

    Drug: Ibrutinib · Drug: Durvalumab

  • Experimental
    Phase 2

    Participants with one of three solid tumor types (Stage III/IV) will be enrolled in the Phase 2 portion of this protocol: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma) and treated at the R2PD of ibrutinib and durvalumab determined in Phase 1b. An interim analysis will be performed to evaluate the response and the safety profile, and the study may be discontinued based on the interim efficacy and/or safety results.

    Drug: Ibrutinib · Drug: Durvalumab

Interventions

  • BTK Inhibitor

    Also known as: PCI-32765

  • Anti PDL-1

    Also known as: MEDI4736

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) and to Find the Recommended Phase II Dose.

    Time frame: From the date of first study treatment until DLT or disease progression per RECIST 1.1.

  2. Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1.

    Time frame: From the date of first study treatment until progressive disease per RECIST 1.1 or unacceptable toxicity.

Secondary outcomes

  1. Phase 1b/2: Pharmacokinetics (Cmax) of Ibrutinib

    Cmax = the peak (maximum) plasma concentration of ibrutinib during the dosing interval on Cycle 3 Day 1.

    Time frame: 0hr, 1hr, 2hr, and 4hr post-dose

  2. Phase 1b/2: Pharmacokinetics (AUC0-24h) of Ibrutinib

    AUC0-24 = the area under the plasma concentration-time curve of ibrutinib during the dosing interval on Cycle 3 Day 1

    Time frame: 0hr, 1hr, 2hr, and 4hr post-dose

  3. Phase 1b/2: Pharmacokinetics (Cmax) of Durvalumab (MEDI4736)

    Cmax = the peak (maximum) plasma concentration of durvalumab (MEDI4736) after administration on Cycle 6 Day 1.

    Time frame: 60 minutes post-dose (dose administered as an infusion over a 1 hour period)

  4. Phase 1b/2: Pharmacokinetics (Ctrough) of Durvalumab (MEDI4736)

    Ctrough = the trough plasma concentration of durvalumab (MEDI4736) after administration on Cycle 6 Day 1

    Time frame: Pre-dose

  5. Phase 1b: Pharmacodynamics

    BTK occupancy

    Time frame: From the date of first study treatment until DLT or disease progression per RECIST 1.1.

  6. Phase 2: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736)

    Time frame: From the date of first study treatment until DLT or disease progression per RECIST 1.1.

  7. Phase 2: Pharmacodynamics

    BTK binding site occupancy of ibrutinib was measured from peripheral blood samples collected from participants during Cycle 3 Day 1.

    Time frame: Pre-dose

07

Results

Posted Jan 3, 2019

Participant flow

Period 1
Participant flow — Period 1
MilestonePhase 1bPhase 2
Started70
Completed60
Not completed10
Withdrew: Other varied reasons10
Period 2
Participant flow — Period 2
MilestonePhase 1bPhase 2
Started0124
Completed00
Not completed0124
Withdrew: Withdrawal by subject014
Withdrew: Death084
Withdrew: Lost to follow-up02
Withdrew: Study terminated by sponsor014
Withdrew: Other varied reasons010

Outcome measures

PrimaryPhase 1b: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) and to Find the Recommended Phase II Dose.
Time frame:
From the date of first study treatment until DLT or disease progression per RECIST 1.1.
Reported as:
Number · participants
Phase 1b: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) and to Find the Recommended Phase II Dose.
participantsPhase 1b
Phase 1b: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) and to Find the Recommended Phase II Dose.6
PrimaryPhase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1.
Time frame:
From the date of first study treatment until progressive disease per RECIST 1.1 or unacceptable toxicity.
Reported as:
Count of participants · Participants
Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1.
ParticipantsPhase 2
Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1.2
SecondaryPhase 1b/2: Pharmacokinetics (Cmax) of Ibrutinib

Cmax = the peak (maximum) plasma concentration of ibrutinib during the dosing interval on Cycle 3 Day 1.

Time frame:
0hr, 1hr, 2hr, and 4hr post-dose
Reported as:
Mean · ng/mL
Phase 1b/2: Pharmacokinetics (Cmax) of Ibrutinib
ng/mLPhase 1b/2 (Pharmacokinetic Population)
Phase 1b/2: Pharmacokinetics (Cmax) of Ibrutinib218 ± 163
SecondaryPhase 1b/2: Pharmacokinetics (AUC0-24h) of Ibrutinib

AUC0-24 = the area under the plasma concentration-time curve of ibrutinib during the dosing interval on Cycle 3 Day 1

Time frame:
0hr, 1hr, 2hr, and 4hr post-dose
Reported as:
Mean · h.ng/mL
Phase 1b/2: Pharmacokinetics (AUC0-24h) of Ibrutinib
h.ng/mLPhase 1b/2 (Pharmacokinetic Population)
Phase 1b/2: Pharmacokinetics (AUC0-24h) of Ibrutinib2126 ± 1315
SecondaryPhase 1b/2: Pharmacokinetics (Cmax) of Durvalumab (MEDI4736)

Cmax = the peak (maximum) plasma concentration of durvalumab (MEDI4736) after administration on Cycle 6 Day 1.

Time frame:
60 minutes post-dose (dose administered as an infusion over a 1 hour period)
Reported as:
Geometric mean · μg/mL
Phase 1b/2: Pharmacokinetics (Cmax) of Durvalumab (MEDI4736)
μg/mLPhase 1b/2 (Pharmacokinetic Population)
Phase 1b/2: Pharmacokinetics (Cmax) of Durvalumab (MEDI4736)386 ± 19.5
SecondaryPhase 1b/2: Pharmacokinetics (Ctrough) of Durvalumab (MEDI4736)

Ctrough = the trough plasma concentration of durvalumab (MEDI4736) after administration on Cycle 6 Day 1

Time frame:
Pre-dose
Reported as:
Geometric mean · μg/mL
Phase 1b/2: Pharmacokinetics (Ctrough) of Durvalumab (MEDI4736)
μg/mLPhase 1b/2 (Pharmacokinetic Population)
Phase 1b/2: Pharmacokinetics (Ctrough) of Durvalumab (MEDI4736)168 ± 19.6
SecondaryPhase 1b: Pharmacodynamics

BTK occupancy

Time frame:
From the date of first study treatment until DLT or disease progression per RECIST 1.1.

No measurements were reported for this outcome.

SecondaryPhase 2: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736)
Time frame:
From the date of first study treatment until DLT or disease progression per RECIST 1.1.
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736)
ParticipantsPhase 2
Phase 2: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736)122
SecondaryPhase 2: Pharmacodynamics

BTK binding site occupancy of ibrutinib was measured from peripheral blood samples collected from participants during Cycle 3 Day 1.

Time frame:
Pre-dose
Reported as:
Mean · percentage of BTK binding site occupancy
Phase 2: Pharmacodynamics
percentage of BTK binding site occupancyPhase 2
Phase 2: Pharmacodynamics87.8 ± 4.2

Adverse events

Collected over 2 years, 5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b/296/122 (78.7%)77/122 (63.1%)122/122 (100%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventPhase 1b/2
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)14/122
PneumoniaHepatobiliary disorders8/122
PneumoniaInfections and infestations8/122
PyrexiaGeneral disorders6/122
DehydrationMetabolism and nutrition disorders6/122
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/122
DyspnoeaRespiratory, thoracic and mediastinal disorders5/122
Pleural effusionRespiratory, thoracic and mediastinal disorders5/122
Abdominal painGastrointestinal disorders4/122
SepsisInfections and infestations4/122
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPhase 1b/2
FatigueGeneral disorders53/122
NauseaGastrointestinal disorders33/122
Decreased appetiteMetabolism and nutrition disorders32/122
HypomagnesaemiaMetabolism and nutrition disorders28/122
AnaemiaBlood and lymphatic system disorders26/122
Oedema peripheralGeneral disorders26/122
DiarrhoeaGastrointestinal disorders22/122
ConstipationGastrointestinal disorders21/122
DyspnoeaRespiratory, thoracic and mediastinal disorders21/122
Abdominal painGastrointestinal disorders19/122

Baseline characteristics

Baseline analysis population includes all patients that received at least one dose of study treatment.

Age, Categorical
Age, Categorical(Participants)Phase 1b/2
<=18 years0
Between 18 and 65 years78
>=65 years44
Age, Continuous
Age, Continuous(years)Phase 1b/2
Mean60.0 ± 12.03
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b/2
Female75
Male47
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b/2
Hispanic or Latino6
Not Hispanic or Latino116
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b/2
American Indian or Alaska Native1
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American11
White104
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)Phase 1b/2
United States122
08

Study locations

17 sites
  • Birmingham, Alabama 35294, United States
  • Scottsdale, Arizona 85258, United States
  • La Jolla, California 92093, United States
  • Los Angeles, California 90025, United States
  • Los Angeles, California 90048, United States
  • Palo Alto, California 94305, United States
  • San Francisco, California 94115, United States
  • Gainesville, Florida 32610, United States
  • Orlando, Florida 32806, United States
  • Chicago, Illinois 60637, United States
  • Peoria, Illinois 61615, United States
  • Hackensack, New Jersey 07601, United States
  • Durham, North Carolina 27710, United States
  • Germantown, Tennessee 38120, United States
  • Nashville, Tennessee 37212, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Aug 2017, 29 months.

Results were first posted in Jan 2019, 1 year 5 months after primary completion.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 29 months is below that.

Counting every sponsor, half of 435 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2015
First posted
Mar 31, 2015
StartActual
Mar 2015
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Results first posted
Jan 3, 2019
Last update
Jan 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02403271
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Mar 31, 2015
Start date
Mar 2015
Primary completion
Aug 2017
Completion
Aug 2017
Results posted
Jan 3, 2019
Last update
Jan 3, 2019

Study contacts

Isaiah Dimery
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion